EZH2 and lymphoma: Preclinical studies demonstrated that valemetostat is superior to an EZH2 selective inhibitor OR-S0 in terms of H3K27me3 depletion and antitumor efficacy.702 In a phase II trial of valemetostat in R/R adult T-cell leukemia/lymphoma (ATL) (NCT04102150), this inhibitor showed promising efficacy and tolerability, i.